Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEM-102 vs Linezolid in ABSSI
NCT00948142Phase 2Completed
- Sponsor
- Arrevus
- Start
- Aug 2009
- Primary completion
- Mar 2010
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fusidic acid in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Arrevus. Started Aug 2009; status: completed.
02
Drugs
fusidic acid
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT00948142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948142.